Nirmatrelvir + ritonavir added to COVID-19 Invitation for Expression of Interest (EOI)
M
Nirmatrelvir 150mg tablets + ritonavir 100mg tablets invited for COVID-19.
Report on the review of regulatory flexibilities/agilities as implemented by National Regulatory Authorities during Covid-19 pandemic
ID
IVD
IS
M
V
VCP
See full report:
Nitrosamine concerns in rifampicin products - Update
M
A nitrosamine impurity, 1-methyl-4-nitrosopiperazine (MeNP), was identified in rifampicin products.
1st Invitation to Manufacturers of therapeutics against Ebola Virus Disease to submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Unit published
M
A 1st Invitation to Manufacturers of therapeutics against Ebola Virus Disease to submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Unit is being published by
Casirivimab and imdevimab combination invited for COVID-19
M
Casirivimab and imdevimab combination invited for COVID-19.
Tocilizumab and sarilumab invited for COVID-19
M
Tocilizumab and sarilumab invited for COVID-19.
IMPORTANT WITHDRAWAL NOTICE - AmBisome Liposomal Amphotericin B 50mg Powder for Concentrate for Dispersion for Infusion (HA705) - Minisart® Filter
IS
M
On 05 February 2021, Gilead Sciences Ltd.
First ever vaccine listed under WHO emergency use
V
On 13 November 2020, WHO listed the nOPV2 vaccine (Bio Farma, Indonesi
Nitrosamine concerns for Priftin (rifapentine) - Update
M
WHO Prequalification Unit - Medicines Assessment Team (PQT/MED) has been in contact with Sanofi regarding the presence of 1-cyclopentyl-4-nitrosopiperazine (CPNP) in their tuberculosis treatment -